A tailor-made oncology treatment, CAR T-cell therapy promises to transform cancer care. But can its potential overcome its problems?
Galleri, a test developed by California-based healthcare company Grail, can detect dozens of types of cancer — most of which currently lack a recommended screening test — with a single blood sample. What could that mean for the way clinicians screen for and treat cancer?
Just as in politics and the energy business, hacking hospital systems is on the rise — and it’s not just patient privacy that’s at risk. In April, a security breach of oncology and radiology system provider Elekta took the radiation systems of numerous...
Initial results from the Southwest Oncology Group (SWOG) phase 3 RxPONDER trial demonstrate that postmenopausal women with a common form of breast cancer may be able to forego chemotherapy — and its potential adverse effects — in favor of standalone hormone therapy.
Ongoing research offers new promise for patients with metastasized, castration-resistant prostate cancer.
Endoscopic submucosal dissection was shown to be highly effective at removing superficial gastric tumors and is a viable option for patients around the globe.
Two recently approved treatments show promise in a new study.
New guidelines on how to treat hereditary breast cancer could be a gamechanger.
The recent FDA approval of the drug Tukysa (tucatinib) for use with the chemotherapeutic agents trastuzumab and capecitabine provides a new treatment option to certain adults with HER2-positive breast cancer.
Study Suggests Connection Between Ovarian Cancer and Fibrosis, Provides Possible Risk Management Option
A recent study in Ottawa poses a connection between ovarian fibrosis and the risk of developing ovarian cancer, and hints at a drug that may decrease that risk.
- 1 of 10
- next ›